Phase II open-label study of MF59-adjuvanted pandemic H1N1 vaccine with or without seasonal trivalent influenza vaccine in healthy adults and elderly subjects

Phase 2, open-label trial of monovalent H1N1 influenza virus vaccine and seasonal trivalent influenza vaccine in influenza (5 arms), sponsored by Novartis. Primary endpoints: Geometric mean hemagglutination inhibition titer, Geometric mean ratio of hemagglutination inhibition titers and 7 more. Started Jul 2009; status: completed.